Generics and Pharmaceuticals

What can be done to convince pharmaceutical firms to lower prescription drug prices?

When the news broke that Martin Shkreli, now the former CEO at Turing Pharmaceuticals, decided to increase the price of the life-saving drug, Daraprim, from $1,130 to $63,000, it made headlines all over the world. A price increase of more than 5,000 percent is probably not justified by high research and marketing costs. More likely

The influence of generic drug production on developing countries

Due to the difficulty in accessing drugs from brand-name pharmaceutical companies, most patients in developing nations are heavily relying on less-expensive generic drugs.

One inhibiting issue is that of patenting and intellectual property protection. The World Trade Organization’s law stipulates that patents should last for 20 years from the registration date. This presumably will provide the

Time Is Running Out – – for Marketplace Coverage

Open enrollment for the Health Insurance Marketplace ends January 31 for 2016 coverage. A growing number of people shop for their health insurance coverage during the last months of the year using the Health Insurance Marketplace or a state-based insurance exchange. Unfortunately, many of the people who are eligible for financial assistance through the Affordable

Stock Prices of Pharmaceutical Companies Working to Address Ebola

In the race for a cure for one of the world’s deadliest epidemics, it may sound insensitive to raise the issue of share prices. But at the heart of this crisis is a story of potential corporate winners and losers as each tries to address Ebola.

Ebola was first discovered in 1976. Despite all the progress

2020-10-28T13:57:53-05:00Tags: , |
Go to Top